CAS: 552292-08-7; (5S,8S)-8-(((R)-1-(3,5-Bis(Trifluoromethyl)Phenyl)Ethoxy)Methyl)-8-Phenyl-1,7-Diazaspiro[4.5]Decan-2-One

结构式图片

欧盟法规

C&L通报

上下游产品

Methyl 3-[(3S,6S)-6-({(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy}Methyl)-3-Nitro-6-Phenylpiperidin-3-Yl]Propanoate 1065272-04-9
Benzyl (2S)-2-[[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]Methyl]-5-(Hydroxymethyl)-5-[(2-Methylpropan-2-yl)Oxycarbonylamino]-2-Phenylpiperidine-1-Carboxylate 552293-48-8
Benzyl (2S)-2-[[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]Methyl]-5-(3-Methoxy-3-Oxoprop-1-Enyl)-5-[(2-Methylpropan-2-yl)Oxycarbonylamino]-2-Phenylpiperidine-1-Carboxylate
罗拉吡坦中间体1 Benzyl (2S)-2-[[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]Methyl]-5-Oxo-2-Phenylpiperidine-1-Carboxylate 552293-37-5

合成工艺路线路线简述

    Methyl 3-[(3S,6S)-6-({(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy}Methyl)-3-Nitro-6-Phenylpiperidin-3-Yl]Propanoate Methylsulfonate置于溶剂黄146,锌,盐酸,Sodium Carbonate体系中,用 水,甲苯 作为反应溶剂,化学反应生成 罗拉吡坦
    参考文献:Hydrochloride Salts Of 8-[{1-(3,5-Bis-(Trifluoromethyl)Phenyl)-Ethoxy)-Methyl]-8-Phenyl-1,7-Diaza-Spiro[4.5]Decan-2-One And Preparation Process Therefor
    标题:Hydrochloride Salts Of 8-[{1-(3,5-Bis-(Trifluoromethyl)Phenyl)-Ethoxy)-Methyl]-8-Phenyl-1,7-Diaza-Spiro[4.5]Decan-2-One And Preparation Process Therefor
    摘要:本发明揭示了盐酸盐和对甲苯磺酸盐形式的(5S,8S)-8-[{(1R)-1-(3,5-双(三氟甲基)苯基)-乙氧基}-甲基]-8-苯基-1,7-二氮杂螺[4.5]癸烷-2-酮,由化学式i表示,并且揭示了制备这些盐的方法.

    海关参考信息

    专利信息


    专利号:US-9260428-B2
    优先权日:2007-03-22
    标 题 :Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds
    发明人:MERGELSBERG INGRID; SCHERER DOMINIK HERMANN; HUTTENLOCH MONIKA ERIKA; TSUI HON-CHUNG; PALIWAL SUNIL; SHIH NENG-YANG
    权利人:OPKO HEALTH INC
    摘要:This application discloses a process to synthesize 8-({1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-pheny-1.7-diaza-spiro[4.5]decan-2-one comprising reacting a compound of the Formula 27a-sulfonate with zinc in the presence of acetic acid.

    专利号:US-9822116-B2
    优先权日:2008-09-05
    标 题:Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds
    发明人:WU GEORGE G; WERNE GERALD; FU XIAOYONG; ORR ROBERT K; CHEN FRANK XING; CUI JIAN; SPRAGUE VICTORIA M; ZHANG FUCHENG; XIE JI; ZENG LIANSHENG; CASTELLANOS LOUIS PETER; CHEN YUYIN; POIRIER MARC; MERGELSBERG INGRID
    权利人:OPKO HEALTH INC
    摘要:This application discloses a novel process to synthesize 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds, which may be used, for example, as NK-1 inhibitor compounds in pharmaceutical preparations, intermediates useful in said process, and processes for preparing said intermediates; also disclosed is a process for removal of metals from N-heterocyclic carbine metal complexes.

    专利号:US-2022118123-A1
    优先权日:2019-02-22
    标 题 :Combination of ar antagonists and targeted thorium conjugates
    发明人:HAMMER STEFANIE; HAGEMANN URS BEAT; HAENDLER BERNARD; LEJEUNE PASCALE; ZITZMANN-KOLBE SABINE; SCHATZ CHRISTOPH; KARLSSON JENNY
    权利人:BAYER AG; BAYER AS
    摘要:The present invention covers combinations of at least two components, component A and component B, comprising component A being PSMA-TTC, and component B being an antiandrogen selected form AR antagonists such as from cyproterone acetate, bicalutamide, flutamide, nilutamide, enzalutamide, apalutamide, darolutamide or keto-darolutamide, or an AR degrader such as ARV-110, or an ARN-terminal domain binder such as EPI-506, or an antisense oligonucleotide that reduces AR expression such as EZN-4176 or AZD-5312, or an androgen synthesis inhibitor such as abiraterone, particularly abiraterone acetate, seviteronel, galeterone, orteronel or ketoconazole, or a dual AR antagonist and androgen synthesis inhibitor such as ODM-204. Another aspect of the present invention covers the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of a hyper-proliferative disease.

    专利号:US-2025162973-A1
    优先权日:2022-02-22
    标题:Methods of synthesis and uses of agrimol compounds
    发明人:CHE CHI MING; FU ZHIWEN; LEUNG YIU CHUNG GULICE
    权利人:VERSITECH LTD; LABORATORY FOR SYNTHETIC CHEMISTRY AND CHEMICAL BIOLOGY LTD
    摘要:Synthetic agrimol B and derivatives thereof (“compoundsâ€?) that have anticancer properties are disclosed. Methods for synthesizing the compounds with an overall yield ≥7% are disclosed. Pharmaceutical formulations in forms suitable for the delivery of the compounds to a subject in need thereof are disclosed. Methods of using the compounds for treating a cancer, reducing a cancer, or treating or ameliorating one or more symptoms associated with a cancer, such as non-small-cell lung cancer, in a subject are also disclosed. The methods include (i) administering to the subject the pharmaceutical formulation containing one or more compounds, for one or more times. The compounds can selectively kill cancer cells and/or cancer stem cells over noncancerous cells by inducing mitochondria dysfunction and/or inhibiting ER to Golgi trafficking in the cancer cells and/or cancer stem cells.

    专利号:US-2014024834-A1
    优先权日:2007-03-22
    标题:Process and intermediates for the synthesis of 8-[-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds

    专利号:US-10000493-B2
    优先权日:2007-03-22
    标 题:Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds
    台州嘉诺华生物科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.canova.com.cn
    企业联系电话:0576-81122208、81101151👤
    📞台州嘉诺华生物科技有限公司 ⚠️参考联系方式

    电话:0576-81122208、81101151

    传真:0576-81122207
    邮箱:canova@canova.com.cn
    通信地址: 台州市黄岩区西城街道县前社区塔院头路76号
    邮编:
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:台州市黄岩区西城街道县前社区塔院头路76号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Salama EA, Elgammal Y, Utturkar SM, Lanman NA, Hazbun TR, Seleem MN. Overcoming amphotericin B resistance in Candida auris using the antiemetic drug rolapitant. Antimicrob Agents Chemother. 2024 Oct
    10:e0055624. doi: 10.1128/aac.00556-24. Epub ahead of print. 22(1):195. doi: 10.1186/s12964-024-01519-8.
    4: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Rolapitant. 2024 Mar 1. 71(1):213-222. doi: 10.1002/bab.2533. Epub 2023 Oct 30. 31(2):95-105. doi: 10.1007/s40199-023-00463-1. Epub 2023 May 24.

    合成参考文献


    参考文献:10.1002/cpt.637
    摘要:Wang X, Zhang ZY, Powers D, Wang J, Lu S, Kansra V. Rolapitant Absolute Bioavailability and PET Imaging Studies in Healthy Adult Volunteers. Clin Pharmacol Ther. 2017 Aug;102(2):332–9. doi: 10.1002/cpt.637.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知